P- Reviewers: Martins WP, Tsalafoutas I S- Editor: Wen LL L- Editor: Roemmele A E- Editor: Liu SQ
Published online Dec 28, 2013. doi: 10.4329/wjr.v5.i12.468
Revised: October 31, 2013
Accepted: November 15, 2013
Published online: December 28, 2013
Microbubbles have been used for many years now in clinical practice as contrast agents in ultrasound imaging. Recently, their therapeutic applications have also attracted more attention. However, the short circulation time (minutes) and relatively large size (two to ten micrometers) of currently used commercial microbubbles do not allow effective extravasation into tumor tissue, preventing efficient tumor targeting. Fortunately, more multifunctional and theranostic nanoparticles with some special advantages over the traditional microbubbles have been widely investigated and explored for biomedical applications. The way to synthesize an ideal ultrasound contrast agent based on nanoparticles in order to achieve an expected effect on contrast imaging is a key technique. Currently a number of nanomaterials, including liposomes, polymers, micelles, dendrimers, emulsions, quantum dots, solid nanoparticles etc., have already been applied to pre or clinical trials. Multifunctional and theranostic nanoparticles with some special advantages, such as the tumor-targeted (passive or active), multi-mode contrast agents (magnetic resonance imaging, ultrasonography or fluorescence), carrier or enhancer of drug delivery, and combined chemo or thermal therapy etc., are rapidly gaining popularity and have shown a promising application in the field of cancer treatment. In this mini review, the trends and the advances of multifunctional and theranostic nanoparticles are briefly discussed.
Core tip: The theranostic nanoparticles are defined as nanoparticles with double functions (for both therapeutic and diagnostic purposes) and are commonly applied to simultaneous drug delivery and molecular imaging.
- Citation: Zheng SG, Xu HX, Chen HR. Nano/microparticles and ultrasound contrast agents. World J Radiol 2013; 5(12): 468-471
- URL: https://www.wjgnet.com/1949-8470/full/v5/i12/468.htm
- DOI: https://dx.doi.org/10.4329/wjr.v5.i12.468
Conventionally, the ultrasound contrast agents (UCAs) commercially used are microbubbles with sizes in the micrometer range, such as SonoVue®, Definity®, Luminity®, Sonazoid®etc., which are mainly composed of insoluble gas (perfluorocarbons or sulfur hexafluoride) and an encapsulating shell (lipids, proteins or polymers)[1-5]. During the past decades, these UCAs were mainly used for imaging in clinical practice[2-11]. Recently, microbubbles and their associated cavitation are playing an increasingly significant role in both diagnostic and therapeutic applications of ultrasound. Besides that, microbubbles have also attracted more attention as carriers and enhancers of drug and gene delivery and have been widely investigated for these applications (especially in the area of anticancer research). However, short circulation time (minutes) and relatively large size (two to ten micrometers) of currently used commercial microbubbles do not allow effective extravasation into tumor tissue (pore size of tumor endothelium is typically in the range 380-780 nm), preventing efficient tumor targeting[14,15].
Fortunately, with the development of nanotechnology, nanomaterials have also evolved and now are widely recognized as a novel type of biomaterial, with very promising applications in the field of drug delivery[13,16-21]. Currently, a number of nanomaterials, including liposomes, polymers, micelles, dendrimers, emulsions, quantum dots, solid nanoparticles etc., have already been applied to pre or clinical trials[22-30]. In theory, nanomaterials can overcome the aforementioned shortcomings of microbubbles due to their smaller sizes (in the nanometer range)[29,31,32]. The National Cancer Institute has defined the nanoparticle as any particle with at least one dimension under 100 nm, while in many articles, some sub-micrometer particles have also been regarded as nanoparticles.
The way to synthesize an ideal ultrasound contrast agent based on nanoparticles in order to achieve an expected effect on contrast imaging is a key technique. According to some recently published articles, most researchers were able to enhance the acoustic backscatter by using nanomaterial equipped with gas (perfluorocarbon), although the nanoparticle-based contrast agents for the imaging modalities discussed were in various stages of development[25-27,33-35].
The use of nanomaterials as carriers for drug delivery represents the mainstream in the field of biomedical research[29,31,36-39]. However, recently, multifunctional and theranostic nanoparticles with some special advantages, such as the tumor-targeted (passive or active), multi-mode contrast agents [magnetic resonance imaging (MRI), ultrasonography (US) or fluorescence], carrier or enhancer of drug delivery, and combined chemo or thermal therapy, etc., are rapidly gaining popularity and have shown a promising application in the field of cancer treatment[13,18-20,29,38-42].
For instance, Lammers et al discussed the principles, pitfalls and (pre) clinical progress of drugs (including those with nanoparticles) used for tumor-targeting. Most nanoparticles can be easily functionalized with a wide variety of biomolecules or antibodies and could be used for the targeted recognition or imaging of specific tissue/organs[19,43-47]. Besides, regarding its multifunction and multi-mode imaging, Malvindi et al reported a magnetic/silica nanocomposite as a dual-mode contrast agent for combined MRI and US which enables non-invasive detection of the molecular components of pathological processes through multiple-mode imaging techniques[14,48]. Wang et al proposed that Au nanoparticle coated mesoporous silica nanocapsule-based enhancement agents can be used as an inorganic theranostic platform for contrast-intensified US imaging, combined chemotherapy and efficient high intensity focused ultrasound tumor ablation[42,45,49].
We hope that the information presented in this mini review will stimulate the readers’ interest regarding the field of nano/microparticles and UCAs.
|1.||Mullin LB, Phillips LC, Dayton PA. Nanoparticle delivery enhancement with acoustically activated microbubbles. IEEE Trans Ultrason Ferroelectr Freq Control. 2013;60:65-77. [PubMed] [DOI]|
|2.||Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D’Onofrio M. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med. 2008;29:28-44. [PubMed] [DOI]|
|3.||Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39:187-210. [PubMed] [DOI]|
|4.||Xu HX. Contrast-enhanced ultrasound: The evolving applications. World J Radiol. 2009;1:15-24. [PubMed] [DOI]|
|5.||Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol. 2007;17:1995-2008. [PubMed] [DOI]|
|6.||Xu HX. Contrast-enhanced ultrasound in the biliary system: Potential uses and indications. World J Radiol. 2009;1:37-44. [PubMed] [DOI]|
|7.||Xu HX. Era of diagnostic and interventional ultrasound. World J Radiol. 2011;3:141-146. [PubMed] [DOI]|
|8.||Xu HX, Lu MD. The current status of contrast-enhanced ultrasound in China. J Med Ultrason. 2010;37:97-106. [DOI]|
|9.||Liu GJ, Lu MD. Diagnosis of liver cirrhosis with contrast-enhanced ultrasound. World J Radiol. 2010;2:32-36. [PubMed] [DOI]|
|10.||Ignee A, Straub B, Schuessler G, Dietrich CF. Contrast enhanced ultrasound of renal masses. World J Radiol. 2010;2:15-31. [PubMed] [DOI]|
|11.||Molins IG, Font JM, Alvaro JC, Navarro JL, Gil MF, Rodríguez CM. Contrast-enhanced ultrasound in diagnosis and characterization of focal hepatic lesions. World J Radiol. 2010;2:455-462. [PubMed] [DOI]|
|12.||Stride EP, Coussios CC. Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng H. 2010;224:171-191. [PubMed]|
|13.||Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm. 2010;7:1959-1973. [PubMed] [DOI]|
|14.||Casciaro S, Soloperto G, Greco A, Casciaro E, Franchini R, Conversano F. Effectiveness of functionalized nanosystems for multimodal molecular sensing and imaging in medicine. IEEE Sens J. 2013;6:2305-2312. [DOI]|
|15.||Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-284. [PubMed]|
|16.||Suzuki R, Oda Y, Utoguchi N, Namai E, Taira Y, Okada N, Kadowaki N, Kodama T, Tachibana K, Maruyama K. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release. 2009;133:198-205. [PubMed] [DOI]|
|17.||Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615-627. [PubMed] [DOI]|
|18.||Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052-1063. [PubMed] [DOI]|
|19.||Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-1626. [PubMed] [DOI]|
|20.||Chen Y, Chen H, Zeng D, Tian Y, Chen F, Feng J, Shi J. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano. 2010;4:6001-6013. [PubMed] [DOI]|
|21.||De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133-149. [PubMed]|
|22.||Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257-288. [PubMed] [DOI]|
|23.||Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171-183. [PubMed] [DOI]|
|24.||Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160. [PubMed] [DOI]|
|25.||Chung MF, Chen KJ, Liang HF, Liao ZX, Chia WT, Xia Y, Sung HW. A liposomal system capable of generating CO2 bubbles to induce transient cavitation, lysosomal rupturing, and cell necrosis. Angew Chem Int Ed Engl. 2012;51:10089-10093. [PubMed] [DOI]|
|26.||Wang X, Chen H, Chen Y, Ma M, Zhang K, Li F, Zheng Y, Zeng D, Wang Q, Shi J. Perfluorohexane-encapsulated mesoporous silica nanocapsules as enhancement agents for highly efficient high intensity focused ultrasound (HIFU). Adv Mater. 2012;24:785-791. [PubMed] [DOI]|
|27.||Kang E, Min HS, Lee J, Han MH, Ahn HJ, Yoon IC, Choi K, Kim K, Park K, Kwon IC. Nanobubbles from gas-generating polymeric nanoparticles: ultrasound imaging of living subjects. Angew Chem Int Ed Engl. 2010;49:524-528. [PubMed] [DOI]|
|28.||Wang L, Shi J, Zhang H, Li H, Gao Y, Wang Z, Wang H, Li L, Zhang C, Chen C. Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials. 2013;34:262-274. [PubMed] [DOI]|
|29.||Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol. 2011;726:325-338. [PubMed] [DOI]|
|30.||Chen H, Li B, Ren X, Li S, Ma Y, Cui S, Gu Y. Multifunctional near-infrared-emitting nano-conjugates based on gold clusters for tumor imaging and therapy. Biomaterials. 2012;33:8461-8476. [PubMed] [DOI]|
|31.||Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175-187. [PubMed] [DOI]|
|32.||Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822. [PubMed] [DOI]|
|33.||Liberman A, Martinez HP, Ta CN, Barback CV, Mattrey RF, Kono Y, Blair SL, Trogler WC, Kummel AC, Wu Z. Hollow silica and silica-boron nano/microparticles for contrast-enhanced ultrasound to detect small tumors. Biomaterials. 2012;33:5124-5129. [PubMed] [DOI]|
|34.||Yang F, Chen P, He W, Gu N, Zhang X, Fang K, Zhang Y, Sun J, Tong J. Bubble microreactors triggered by an alternating magnetic field as diagnostic and therapeutic delivery devices. Small. 2010;6:1300-1305. [PubMed] [DOI]|
|35.||Wang X, Chen H, Zheng Y, Ma M, Chen Y, Zhang K, Zeng D, Shi J. Au-nanoparticle coated mesoporous silica nanocapsule-based multifunctional platform for ultrasound mediated imaging, cytoclasis and tumor ablation. Biomaterials. 2013;34:2057-2068. [PubMed] [DOI]|
|36.||Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198. [PubMed] [DOI]|
|37.||Egusquiaguirre SP, Igartua M, Hernández RM, Pedraz JL. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012;14:83-93. [PubMed] [DOI]|
|38.||Chen Y, Chen H, Guo L, He Q, Chen F, Zhou J, Feng J, Shi J. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano. 2010;4:529-539. [PubMed] [DOI]|
|39.||Chen Y, Chen H, Zhang S, Chen F, Zhang L, Zhang J, Zhu M, Wu H, Guo L, Feng J. Multifunctional Mesoporous Nanoellipsoids for Biological Bimodal Imaging and Magnetically Targeted Delivery of Anticancer Drugs. Adv Funct Mater. 2011;21:270-278. [DOI]|
|40.||Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst. 2007;99:1095-1106. [PubMed]|
|41.||Popović Z, Liu W, Chauhan VP, Lee J, Wong C, Greytak AB, Insin N, Nocera DG, Fukumura D, Jain RK. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010;49:8649-8652. [PubMed] [DOI]|
|42.||Wang ZY, Song J, Zhang DS. Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol. 2009;15:2995-3002. [PubMed]|
|43.||Behnke T, Mathejczyk JE, Brehm R, Würth C, Gomes FR, Dullin C, Napp J, Alves F, Resch-Genger U. Target-specific nanoparticles containing a broad band emissive NIR dye for the sensitive detection and characterization of tumor development. Biomaterials. 2013;34:160-170. [PubMed] [DOI]|
|44.||Liu J, Li J, Rosol TJ, Pan X, Voorhees JL. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol. 2007;52:4739-4747. [PubMed]|
|45.||Sheeran PS, Luois SH, Mullin LB, Matsunaga TO, Dayton PA. Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons. Biomaterials. 2012;33:3262-3269. [PubMed] [DOI]|
|46.||Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649-1659. [PubMed]|
|47.||Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62:284-304. [PubMed] [DOI]|
|48.||Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R. Magnetic/Silica Nanocomposites as Dual-Mode Contrast Agents for Combined Magnetic Resonance Imaging and Ultrasonography. Adv Funct Mater. 2011;21:2548-2555. [DOI]|
|49.||Wei H, Huang J, Yang J, Zhang X, Lin L, Xue E, Chen Z. Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts. PLoS One. 2013;8:e58133. [PubMed] [DOI]|
|50.||Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, Yang SX, Ping JL. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol. 2009;15:1966-1972. [PubMed]|